SEATTLE & PALO ALTO, Calif.--(BUSINESS WIRE)--The University of Washington Center for Commercialization (UW C4C) and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties. The agreement settles a U.S. patent interference concerning previously competing applications that describe methods to determine proper dosing of the popular anti-coagulant drug, warfarin. Pharmigene is now the global licensee of VKORC1-1639 SNP related patents and application from both the University of Washington and Academia Sinica, Taiwan. Pharmigene now offers the most complete VKORC1-1639 SNP patent portfolio to drive development and commercialization of genetic tests that reduce warfarin-related adverse drug events.
